Letters, Testimony & Comments

BIO’s comments to the USDA on the biomass crop assistance program enacted by the 2008 Farm Bill

The Biotechnology Industry Organization (BIO) appreciates the opportunity to provide comments on the proposed regulations to implement the Biomass Crop Assistance Program (BCAP) enacted by the Food, Conservation, and Energy Act of 2008 (Farm Bill...

BIO Submits "Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use" Comments to the European Medicines Agency (EMA)

BIO provides specific comments and requests clarifications on the text of the Guideline regarding the variability of immunogenicity, approaches for predicting and reducing immunogenicity, clinical consequences of immunogenicity, problems with...

MMA Legislative Text

Full Text of the Medicare Modernization Act, Medicare Prescription Drug and Modernization Act of 2003, Public Law 108-173

Read Congresswoman Anna Eshoo's statement introducing H.R. 5629, The Pathway for Biosimilars Act

Read a summary of H.R. 5629

Complete text of H.R. 5629

BIO Urges Congress to Prioritize Patient Safety and Biomedical Innovation in Pathway for Follow-On Biologics

BIO Testimony Opposing Alaska Senate Bill 25

BIO Testimony Opposing Alaska Senate Bill 25, a bill to label biotech fish and fish products.

BIO letter to Sonoma County Board of Supervisors

Letter to Sonoma County Board of Supervisors outlining BIO’s concerns with the potential implications of the Sonoma County proposed initiative to ban transgenic organisms.

Arkansas House Bill 2574

Letter expressing BIO’s concerns with House Bill 2574 (“Certified Rice Act”)

BIO Testimony opposing Alaska Senate Bill 281

SB 281 propose to require labeling of biotech fish and fish products (Mar. 3, 2004).

Letter to the Honorable John Carey

Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.